Investor Relations

Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Company Overview

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”). Our goal is to develop a novel and proprietary class of NaV blockers that target the body’s peripheral nervous system, initially for Erythromelalgia (“EM”), a rare condition that primarily affects the feet and, less commonly, the hands (extremities). It is characterized by intense, burning pain of affected extremities, severe redness (erythema), and increased skin temperature that may be episodic or almost continuous in nature.

Stock Snapshot

IR Contacts


Chromocell Therapeutics Corporation
4400 Route 9 South
Suite 1000
Freehold, NJ 07728
United States

Investor Relations

Jason Assad
Director of Corporate Communications
T: 678-570-6791

Transfer Agent

Nevada Agency and Transfer Company
Tiffany Baxter
50 West Liberty Street, Suite 880
Reno, NV 89501
United States
T: 775-322-0626

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.